Does the media prefer DNTH or ASND?

In the previous week, Ascendis Pharma A/S had 7 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 2 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.00 beat Ascendis Pharma A/S's score of -0.02 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EXEL or DNTH?

In the previous week, Exelixis had 2 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 4 mentions for Exelixis and 2 mentions for Dianthus Therapeutics. Exelixis' average media sentiment score of 0.74 beat Dianthus Therapeutics' score of 0.00 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SMMT or DNTH?

In the previous week, Summit Therapeutics had 18 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 20 mentions for Summit Therapeutics and 2 mentions for Dianthus Therapeutics. Summit Therapeutics' average media sentiment score of 0.42 beat Dianthus Therapeutics' score of 0.00 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DNTH or BBIO?

In the previous week, BridgeBio Pharma had 2 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 4 mentions for BridgeBio Pharma and 2 mentions for Dianthus Therapeutics. BridgeBio Pharma's average media sentiment score of 0.51 beat Dianthus Therapeutics' score of 0.00 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HALO or DNTH?

In the previous week, Halozyme Therapeutics had 5 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 7 mentions for Halozyme Therapeutics and 2 mentions for Dianthus Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.19 beat Dianthus Therapeutics' score of 0.00 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Dianthus Therapeutics (DNTH) Competitors

$88.21 -0.11 (-0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$88.30 +0.09 (+0.10%)

As of 07:30 PM Eastern

Compare

DNTH vs. ASND, EXEL, SMMT, BBIO, and HALO

Should you buy Dianthus Therapeutics stock or one of its competitors? Dianthus Therapeutics's main competitors and comparable companies include Ascendis Pharma A/S (ASND), Exelixis (EXEL), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Dianthus Therapeutics (NASDAQ:DNTH) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Dianthus Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 7 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 2 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.00 beat Ascendis Pharma A/S's score of -0.02 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascendis Pharma A/S has a net margin of 70.99% compared to Dianthus Therapeutics' net margin of -10,096.95%. Ascendis Pharma A/S's return on equity of 32.54% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Dianthus Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,424.74	-$162.34M	-$4.15	N/A
Ascendis Pharma A/S	$814.57M	17.28	-$258M	$12.89	17.50

Dianthus Therapeutics currently has a consensus price target of $129.83, indicating a potential upside of 43.84%. Ascendis Pharma A/S has a consensus price target of $310.75, indicating a potential upside of 37.74%. Given Dianthus Therapeutics' higher probable upside, research analysts clearly believe Dianthus Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Ascendis Pharma A/S beats Dianthus Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Exelixis has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

In the previous week, Exelixis had 2 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 4 mentions for Exelixis and 2 mentions for Dianthus Therapeutics. Exelixis' average media sentiment score of 0.74 beat Dianthus Therapeutics' score of 0.00 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

85.3% of Exelixis shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Exelixis has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.24	$782.57M	$3.18	18.38
Dianthus Therapeutics	$2.04M	2,424.74	-$162.34M	-$4.15	N/A

Exelixis has a net margin of 35.33% compared to Dianthus Therapeutics' net margin of -10,096.95%. Exelixis' return on equity of 42.17% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Exelixis presently has a consensus target price of $50.29, indicating a potential downside of 13.95%. Dianthus Therapeutics has a consensus target price of $129.83, indicating a potential upside of 43.84%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dianthus Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Exelixis beats Dianthus Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Summit Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -10,096.95%. Dianthus Therapeutics' return on equity of -22.53% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Summit Therapeutics currently has a consensus target price of $28.61, indicating a potential upside of 70.73%. Dianthus Therapeutics has a consensus target price of $129.83, indicating a potential upside of 43.84%. Given Summit Therapeutics' higher possible upside, research analysts plainly believe Summit Therapeutics is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Summit Therapeutics had 18 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 20 mentions for Summit Therapeutics and 2 mentions for Dianthus Therapeutics. Summit Therapeutics' average media sentiment score of 0.42 beat Dianthus Therapeutics' score of 0.00 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Dianthus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Dianthus Therapeutics has higher revenue and earnings than Summit Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Dianthus Therapeutics	$2.04M	2,424.74	-$162.34M	-$4.15	N/A

Summit Therapeutics has a beta of -1.51, indicating that its stock price is 251% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Summary

Dianthus Therapeutics beats Summit Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Dianthus Therapeutics (NASDAQ:DNTH) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Dianthus Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,424.74	-$162.34M	-$4.15	N/A
BridgeBio Pharma	$502.08M	26.10	-$724.93M	-$3.57	N/A

Dianthus Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

BridgeBio Pharma has a net margin of -97.03% compared to Dianthus Therapeutics' net margin of -10,096.95%. BridgeBio Pharma's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Dianthus Therapeutics currently has a consensus target price of $129.83, indicating a potential upside of 43.84%. BridgeBio Pharma has a consensus target price of $102.61, indicating a potential upside of 53.08%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, BridgeBio Pharma had 2 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 4 mentions for BridgeBio Pharma and 2 mentions for Dianthus Therapeutics. BridgeBio Pharma's average media sentiment score of 0.51 beat Dianthus Therapeutics' score of 0.00 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

BridgeBio Pharma beats Dianthus Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Halozyme Therapeutics has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.86	$316.89M	$3.35	32.55
Dianthus Therapeutics	$2.04M	2,424.74	-$162.34M	-$4.15	N/A

Halozyme Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

Halozyme Therapeutics has a net margin of 24.86% compared to Dianthus Therapeutics' net margin of -10,096.95%. Halozyme Therapeutics' return on equity of 260.98% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

In the previous week, Halozyme Therapeutics had 5 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 7 mentions for Halozyme Therapeutics and 2 mentions for Dianthus Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.19 beat Dianthus Therapeutics' score of 0.00 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dianthus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Halozyme Therapeutics presently has a consensus target price of $91.20, indicating a potential downside of 16.35%. Dianthus Therapeutics has a consensus target price of $129.83, indicating a potential upside of 43.84%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dianthus Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Halozyme Therapeutics beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Dianthus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNTH vs. The Competition

Export

Metric	Dianthus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.84B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.76%
P/E Ratio	-21.26	12.93	273.67	26.04
Price / Sales	2,369.56	1,305.45	611.82	91.49
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	7.73	16.63	10.92	6.30
Net Income	-$162.34M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-0.38%	-3.05%	-2.11%	-1.67%
1 Month Performance	-16.97%	-10.75%	-6.34%	-3.94%
1 Year Performance	138.86%	21.11%	8.81%	2.77%

Dianthus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNTH Dianthus Therapeutics	1.7114 of 5 stars	$88.21 -0.1%	$129.83 +47.2%	+126.9%	$4.84B	$2.04M	N/A	92
ASND Ascendis Pharma A/S	4.7691 of 5 stars	$237.57 0.0%	$310.75 +30.8%	+11.4%	$14.82B	$814.57M	18.43	1,189
EXEL Exelixis	3.1761 of 5 stars	$58.15 +1.6%	$50.29 -13.5%	+40.6%	$14.18B	$2.32B	18.29	1,077
SMMT Summit Therapeutics	2.8723 of 5 stars	$17.12 +1.3%	$25.91 +51.3%	-18.5%	$13.48B	N/A	N/A	265	Analyst Forecast
BBIO BridgeBio Pharma	3.0956 of 5 stars	$69.23 +4.0%	$102.61 +48.2%	+25.1%	$13.02B	$502.08M	N/A	839

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNTH) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. ASND, EXEL, SMMT, BBIO, and HALO

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Dianthus Therapeutics compare to Exelixis?

Summary

How does Dianthus Therapeutics compare to Summit Therapeutics?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Summary

How does Dianthus Therapeutics compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. ASND, EXEL, SMMT, BBIO, and HALO

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Which has more volatility and risk, DNTH or ASND?

Does the media prefer DNTH or ASND?

Is DNTH or ASND more profitable?

Do institutionals & insiders believe in DNTH or ASND?

Which has stronger earnings & valuation, DNTH or ASND?

Do analysts recommend DNTH or ASND?

Summary

How does Dianthus Therapeutics compare to Exelixis?

Which has more risk and volatility, EXEL or DNTH?

Does the media favor EXEL or DNTH?

Do institutionals & insiders believe in EXEL or DNTH?

Which has better valuation & earnings, EXEL or DNTH?

Is EXEL or DNTH more profitable?

Do analysts recommend EXEL or DNTH?

Summary

How does Dianthus Therapeutics compare to Summit Therapeutics?

Is SMMT or DNTH more profitable?

Do analysts recommend SMMT or DNTH?

Does the media refer more to SMMT or DNTH?

Do insiders and institutionals hold more shares of SMMT or DNTH?

Which has higher earnings & valuation, SMMT or DNTH?

Which has more volatility & risk, SMMT or DNTH?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Which has higher valuation and earnings, DNTH or BBIO?

Which has more volatility and risk, DNTH or BBIO?

Is DNTH or BBIO more profitable?

Do analysts recommend DNTH or BBIO?

Does the media prefer DNTH or BBIO?

Do insiders and institutionals hold more shares of DNTH or BBIO?

Summary

How does Dianthus Therapeutics compare to Halozyme Therapeutics?

Do insiders & institutionals have more ownership in HALO or DNTH?

Which has higher earnings and valuation, HALO or DNTH?

Which has more volatility and risk, HALO or DNTH?

Is HALO or DNTH more profitable?

Does the media prefer HALO or DNTH?

Do analysts prefer HALO or DNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools